Literature DB >> 7892486

Parenchymal liver enhancement with bolus-triggered helical CT: preliminary clinical results.

L Kopka1, M Funke, U Fischer, R Vosshenrich, J W Oestmann, E Grabbe.   

Abstract

A software-driven device for bolus-triggered start of helical computed tomography (CT) was evaluated in liver studies of 30 patients with suspected metastatic liver disease. Compared with results in a control group of 30 patients who underwent conventional contrast material-enhanced helical CT, the study group had significantly higher and more constant parenchymal enhancement (P < .05, Mann-Whitney U test). This technique helps optimize findings at contrast-enhanced helical CT.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7892486     DOI: 10.1148/radiology.195.1.7892486

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  5 in total

1.  Real-time bolus-triggering technique in helical CT: efficacy in identifying inflow vein thrombosis.

Authors:  R Kickuth; J Kirchner; U Laufer; D Liermann
Journal:  Eur Radiol       Date:  2000       Impact factor: 5.315

2.  Standardisation of liver MDCT by tracking liver parenchyma enhancement to trigger imaging.

Authors:  H Brodoefel; A Tognolini; G A Zamboni; S Gourtsoyianni; C D Claussen; V Raptopoulos
Journal:  Eur Radiol       Date:  2011-11-05       Impact factor: 5.315

3.  Effect of contrast injection protocol with dose tailored to patient weight and fixed injection duration on aortic and hepatic enhancement at multidetector-row helical CT.

Authors:  Kazuo Awai; Shinichi Hori
Journal:  Eur Radiol       Date:  2003-05-08       Impact factor: 5.315

4.  Optimising the scan delay for arterial phase imaging of the liver using the bolus tracking technique.

Authors:  Rs Chan; G Kumar; Bjj Abdullah; Kh Ng; A Vijayananthan; H Mohd Nor; Yw Liew
Journal:  Biomed Imaging Interv J       Date:  2011-04-01

5.  Liver metastases: imaging considerations for protocol development with multislice CT (MSCT).

Authors:  Paul M Silverman
Journal:  Cancer Imaging       Date:  2006-11-08       Impact factor: 3.909

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.